These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12006209)

  • 1. Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy.
    Prince HM; Bashford J; Wall D; Rischin D; Parker N; Toner GC; Seymour JF; Blakey D; Haylock D; Simmons P; Francis P; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P
    Cytotherapy; 2002; 4(2):137-45. PubMed ID: 12006209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CliniMACS CD34-selected cells to support multiple cycles of high-dose therapy.
    Prince HM; Wall D; Rischin D; Toner GC; Seymour JF; Blakey D; Haylock D; Simmons P; Wolf M; Januszewicz EH; Westerman D; Richardson G; Scarlett J; Briggs P
    Cytotherapy; 2002; 4(2):147-55. PubMed ID: 12006210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
    Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
    J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
    Prince HM; Gardyn J; Millward MJ; Rischin D; Francis P; Gates P; Chapple P; Quinn M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P; Brettell M; Toner GC
    Bone Marrow Transplant; 1999 Mar; 23(5):427-35. PubMed ID: 10100555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel effectively mobilizes peripheral blood CD34+ cells.
    Prince HM; Toner GC; Seymour JF; Blakey D; Gates P; Eerhard S; Chapple P; Wall D; Quinn M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P; Brettell M; Rischin D
    Bone Marrow Transplant; 2000 Sep; 26(5):483-7. PubMed ID: 11019836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
    Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
    Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autografting with peripheral blood CD34-positive cells following high-dose chemotherapy against breast cancer.
    Okumura A; Tokuda Y; Ohta M; Suzuki Y; Saito Y; Kuge S; Kubota M; Makuuchi H; Tajima T; Nakamura Y; Hotta T
    Tokai J Exp Clin Med; 1999 Dec; 24(4-6):141-6. PubMed ID: 10819494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer.
    Williams SF; Lee WJ; Bender JG; Zimmerman T; Swinney P; Blake M; Carreon J; Schilling M; Smith S; Williams DE; Oldham F; Van Epps D
    Blood; 1996 Mar; 87(5):1687-91. PubMed ID: 8634412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.
    Filip S; Bláha M; Odrázka K; Mericka P; Vávrová J
    J Hematother Stem Cell Res; 2000 Feb; 9(1):31-8. PubMed ID: 10738969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting purification of CD34(+) peripheral blood stem cells using the Baxter Isolex 300i.
    Gryn J; Shadduck RK; Lister J; Zeigler ZR; Raymond JM
    J Hematother Stem Cell Res; 2002 Aug; 11(4):719-30. PubMed ID: 12201961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD.
    Blystad AK; Torlakovic E; Holte H; Kvaløy S; Lenschow E; Kvalheim G
    Cytotherapy; 2001; 3(4):295-305. PubMed ID: 12171718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
    Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
    J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma.
    Abonour R; Scott KM; Kunkel LA; Robertson MJ; Hromas R; Graves V; Lazaridis EN; Cripe L; Gharpure V; Traycoff CM; Mills B; Srour EF; Cornetta K
    Bone Marrow Transplant; 1998 Nov; 22(10):957-63. PubMed ID: 9849692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow.
    Klein JL; Hamm C; Dansey RD; Karanes C; Abella E; Cassells L; Peters WP; Baynes RD
    Bone Marrow Transplant; 2001 Dec; 28(11):1023-9. PubMed ID: 11781611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy.
    Weaver CH; Hazelton B; Birch R; Palmer P; Allen C; Schwartzberg L; West W
    Blood; 1995 Nov; 86(10):3961-9. PubMed ID: 7579367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
    Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
    Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing collection and engraftment of CD34+ cells in patients with breast cancer following high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation.
    Canales MA; Arrieta R; Hernández-García MC; Ojeda E; Díez J; Calero F; Aguado MJ; Bustos JG; Hernández-Navarro F
    J Hematother Stem Cell Res; 2000 Feb; 9(1):103-9. PubMed ID: 10738978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.